Catalyst Pharmaceuticals Inc (CPRX)

$15.34

-0.66

(-4.13%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Catalyst Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 10 quarters, 35.95M → 110.56M (in $), with an average increase of 11.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -30.76M → 34.84M (in $), with an average increase of 188.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 56.9%

Performance

  • $15.34
    $16.22
    $15.34
    downward going graph

    0.0%

    Downside

    Day's Volatility :5.4%

    Upside

    5.4%

    downward going graph
  • $11.09
    $17.78
    $15.34
    downward going graph

    27.71%

    Downside

    52 Weeks Volatility :37.63%

    Upside

    13.72%

    downward going graph

Returns

PeriodCatalyst Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
8.84%
-0.7%
0.0%
6 Months
20.3%
6.6%
0.0%
1 Year
-10.21%
3.7%
-1.5%
3 Years
271.23%
14.0%
-21.8%

Highlights

Market Capitalization
1.8B
Book Value
$3.62
Earnings Per Share (EPS)
0.63
PE Ratio
24.67
PEG Ratio
0.0
Wall Street Target Price
26.71
Profit Margin
17.93%
Operating Margin TTM
37.71%
Return On Assets TTM
12.83%
Return On Equity TTM
20.75%
Revenue TTM
398.2M
Revenue Per Share TTM
3.75
Quarterly Revenue Growth YOY
82.0%
Gross Profit TTM
160.0M
EBITDA
119.7M
Diluted Eps TTM
0.63
Quarterly Earnings Growth YOY
0.35
EPS Estimate Current Year
1.0
EPS Estimate Next Year
1.41
EPS Estimate Current Quarter
0.26
EPS Estimate Next Quarter
0.32

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Catalyst Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 74.12%

Current $15.34
Target $26.71

Company Financials

FY18Y/Y Change
Revenue
500.0K
-
Net Income
-34.0M
↑ 84.68%
Net Profit Margin
-6.8K%
-
FY19Y/Y Change
Revenue
102.3M
↑ 20361.27%
Net Income
31.9M
↓ 193.74%
Net Profit Margin
31.16%
↑ 6831.86%
FY20Y/Y Change
Revenue
119.1M
↑ 16.39%
Net Income
75.0M
↑ 135.24%
Net Profit Margin
62.97%
↑ 31.81%
FY21Y/Y Change
Revenue
140.8M
↑ 18.27%
Net Income
39.5M
↓ 47.35%
Net Profit Margin
28.03%
↓ 34.94%
FY22Y/Y Change
Revenue
214.2M
↑ 52.1%
Net Income
83.1M
↑ 110.42%
Net Profit Margin
38.79%
↑ 10.76%
FY23Y/Y Change
Revenue
398.2M
↑ 85.9%
Net Income
71.4M
↓ 14.05%
Net Profit Margin
17.93%
↓ 20.86%
Q3 FY22Q/Q Change
Revenue
57.2M
↑ 7.78%
Net Income
22.7M
↑ 5.22%
Net Profit Margin
39.74%
↓ 0.96%
Q4 FY22Q/Q Change
Revenue
60.8M
↑ 6.14%
Net Income
25.5M
↑ 11.97%
Net Profit Margin
41.92%
↑ 2.18%
Q1 FY23Q/Q Change
Revenue
85.4M
↑ 40.5%
Net Income
29.6M
↑ 16.08%
Net Profit Margin
34.64%
↓ 7.28%
Q2 FY23Q/Q Change
Revenue
99.6M
↑ 16.65%
Net Income
37.8M
↑ 27.71%
Net Profit Margin
37.92%
↑ 3.28%
Q3 FY23Q/Q Change
Revenue
102.7M
↑ 3.12%
Net Income
-30.8M
↓ 181.47%
Net Profit Margin
-29.96%
↓ 67.88%
Q4 FY23Q/Q Change
Revenue
110.6M
↑ 7.67%
Net Income
34.8M
↓ 213.26%
Net Profit Margin
31.51%
↑ 61.47%
FY18Y/Y Change
Total Assets
60.4M
↓ 29.21%
Total Liabilities
9.7M
↑ 118.51%
FY19Y/Y Change
Total Assets
112.4M
↑ 85.9%
Total Liabilities
24.7M
↑ 156.01%
FY20Y/Y Change
Total Assets
192.4M
↑ 71.17%
Total Liabilities
22.8M
↓ 8.04%
FY21Y/Y Change
Total Assets
237.8M
↑ 23.62%
Total Liabilities
31.0M
↑ 36.04%
FY22Y/Y Change
Total Assets
375.6M
↑ 57.97%
Total Liabilities
75.2M
↑ 142.95%
FY23Y/Y Change
Total Assets
471.9M
↑ 25.63%
Total Liabilities
84.0M
↑ 11.72%
Q3 FY22Q/Q Change
Total Assets
333.1M
↑ 24.62%
Total Liabilities
63.1M
↑ 140.58%
Q4 FY22Q/Q Change
Total Assets
375.6M
↑ 12.76%
Total Liabilities
75.2M
↑ 19.24%
Q1 FY23Q/Q Change
Total Assets
407.2M
↑ 8.41%
Total Liabilities
73.6M
↓ 2.18%
Q2 FY23Q/Q Change
Total Assets
443.9M
↑ 9.0%
Total Liabilities
68.6M
↓ 6.75%
Q3 FY23Q/Q Change
Total Assets
413.2M
↓ 6.91%
Total Liabilities
64.7M
↓ 5.74%
Q4 FY23Q/Q Change
Total Assets
471.9M
↑ 14.2%
Total Liabilities
84.0M
↑ 29.94%
FY18Y/Y Change
Operating Cash Flow
-25.7M
↑ 87.04%
Investing Cash Flow
-15.5M
↑ 392169.1%
Financing Cash Flow
293.1K
↓ 99.49%
FY19Y/Y Change
Operating Cash Flow
34.6M
↓ 234.65%
Investing Cash Flow
37.2M
↓ 339.76%
Financing Cash Flow
1.1M
↑ 280.82%
FY20Y/Y Change
Operating Cash Flow
45.0M
↑ 30.12%
Investing Cash Flow
-5.0M
↓ 113.46%
Financing Cash Flow
701.9K
↓ 37.12%
FY21Y/Y Change
Operating Cash Flow
60.4M
↑ 34.06%
Investing Cash Flow
-11.0M
↑ 119.92%
Financing Cash Flow
-8.1M
↓ 1260.08%
FY22Y/Y Change
Operating Cash Flow
116.0M
↑ 92.22%
Investing Cash Flow
9.2M
↓ 183.56%
Financing Cash Flow
1.7M
↓ 120.8%
Q3 FY22Q/Q Change
Operating Cash Flow
41.3M
↑ 57.69%
Investing Cash Flow
-132.0K
↓ 101.41%
Financing Cash Flow
4.0M
↓ 233.16%
Q1 FY23Q/Q Change
Operating Cash Flow
12.1M
↓ 69.88%
Investing Cash Flow
-162.4M
-
Financing Cash Flow
149.0K
↓ 93.39%

Technicals Summary

Sell

Neutral

Buy

Catalyst Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
-0.5%
20.3%
-10.21%
271.23%
201.32%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
24.67
24.67
0.0
1.0
0.21
0.13
NA
3.62
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
Buy
$1.8B
201.32%
24.67
17.93%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    13.42%

  • Deerfield Management Co

    6.95%

  • Vanguard Group Inc

    6.04%

  • State Street Corporation

    5.76%

  • Dimensional Fund Advisors, Inc.

    2.21%

  • Geode Capital Management, LLC

    1.87%

Company Information

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso

Organization
Catalyst Pharmaceuticals Inc
Employees
167
CEO
Mr. Patrick J. McEnany
Industry
Health Technology

Discover More

FAQs